What is Lifecore Biomedical, Inc.'s D&A?

Lifecore Biomedical, Inc. (LFCR) reported D&A of $2.31M in Q1 2026.

How has Lifecore Biomedical, Inc.'s D&A changed year-over-year?

Lifecore Biomedical, Inc.'s D&A increased by 20.7% year-over-year, from $1.91M to $2.31M.

What is the long-term trend for Lifecore Biomedical, Inc.'s D&A?

Over 3 years (2022 to 2025), Lifecore Biomedical, Inc.'s D&A has grown at a -23.7% compound annual growth rate (CAGR), from $18.06M to $8.03M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Lifecore Biomedical, Inc. LFCR D&A

D&A at other companies

Baxter InternationalBAX

$237M-4.0%

ADMA BiologicsADMA

$1.8M-5.3%

Medpace Holdings, Inc.MEDP

$6.75M+0.9%

Biodesix, Inc.BDSX

$1.4M-3.1%

ClearPoint NeuroCLPT

$86K-16.5%

Charles River LaboratoriesCRL

$67.15M-44.2%

Segments

By segment

See full

Reportable Segment$2.31M—

Other financials

Income statement

See full

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Balance sheet

See full

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Cash flow

See full

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Valuation

See full

Market cap$196.92M-35.4%

Enterprise value$333.06M+8.3%

P/S1.6×+0.5×

Profitability

See full

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Returns & leverage

See full

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s D&A?: Lifecore Biomedical, Inc. (LFCR) reported D&A of $2.31M in Q1 2026.
How has Lifecore Biomedical, Inc.'s D&A changed year-over-year?: Lifecore Biomedical, Inc.'s D&A increased by 20.7% year-over-year, from $1.91M to $2.31M.
What is the long-term trend for Lifecore Biomedical, Inc.'s D&A?: Over 3 years (2022 to 2025), Lifecore Biomedical, Inc.'s D&A has grown at a -23.7% compound annual growth rate (CAGR), from $18.06M to $8.03M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.